Sun Pharma Presents Long-term Study Results that Show Significant Skin Clearance with ILUMYAŽ (tildrakizumab-asmn) Maintained Over Four Years in People with Moderate-to-Severe Plaque Psoriasis

Thursday, October 10, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

- Additional data show people with and without metabolic syndrome respond similarly to ILUMYA treatment with comparable, positive results



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Premium Membership Benefits

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store